Phase III Study to Assess Long‐Term (52‐Week) Safety and Efficacy of Mirabegron, a β3‐Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder

ConclusionsThere were no safety or tolerability concerns associated with mirabegron 50 mg (with an optional dose increase to 100 mg) over 52 weeks. Improvement in micturition variables was maintained with mirabegron 50 mg from weeks 8 to 52.
Source: LUTS: Lower Urinary Tract Symptoms - Category: Urology & Nephrology Authors: Tags: ORIGINAL ARTICLE Source Type: research